383 related articles for article (PubMed ID: 12138244)
21. HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer.
Ghadban T; Dibbern JL; Reeh M; Miro JT; Tsui TY; Wellner U; Izbicki JR; Güngör C; Vashist YK
Apoptosis; 2017 Mar; 22(3):369-380. PubMed ID: 27878398
[TBL] [Abstract][Full Text] [Related]
22. Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck.
Skoda C; Erovic BM; Wachek V; Vormittag L; Wrba F; Martinek H; Heiduschka G; Kloimstein P; Selzer E; Thurnher D
Oncol Rep; 2008 Jun; 19(6):1499-503. PubMed ID: 18497956
[TBL] [Abstract][Full Text] [Related]
23. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content.
Bold RJ; Chandra J; McConkey DJ
Ann Surg Oncol; 1999; 6(3):279-85. PubMed ID: 10340887
[TBL] [Abstract][Full Text] [Related]
24. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.
Skrypek N; Vasseur R; Vincent A; Duchêne B; Van Seuningen I; Jonckheere N
Oncotarget; 2015 May; 6(13):10853-67. PubMed ID: 25890497
[TBL] [Abstract][Full Text] [Related]
25. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine.
Galmarini CM; Clarke ML; Falette N; Puisieux A; Mackey JR; Dumontet C
Int J Cancer; 2002 Feb; 97(4):439-45. PubMed ID: 11802204
[TBL] [Abstract][Full Text] [Related]
26. Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion.
Jiang C; Yi XP; Shen H; Li YX
World J Gastroenterol; 2012 Jun; 18(23):2956-65. PubMed ID: 22736919
[TBL] [Abstract][Full Text] [Related]
27. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
Rajabpour A; Afgar A; Mahmoodzadeh H; Radfar JE; Rajaei F; Teimoori-Toolabi L
Cancer Chemother Pharmacol; 2017 Oct; 80(4):765-775. PubMed ID: 28887583
[TBL] [Abstract][Full Text] [Related]
28. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.
Hagmann W; Jesnowski R; Löhr JM
Neoplasia; 2010 Sep; 12(9):740-7. PubMed ID: 20824050
[TBL] [Abstract][Full Text] [Related]
29. Rab14 overexpression regulates gemcitabine sensitivity through regulation of Bcl-2 and mitochondrial function in pancreatic cancer.
Ge J; Ge C
Virchows Arch; 2019 Jan; 474(1):59-69. PubMed ID: 30267303
[TBL] [Abstract][Full Text] [Related]
30. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death.
Arlt A; Gehrz A; Müerköster S; Vorndamm J; Kruse ML; Fölsch UR; Schäfer H
Oncogene; 2003 May; 22(21):3243-51. PubMed ID: 12761494
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line.
Biliran H; Wang Y; Banerjee S; Xu H; Heng H; Thakur A; Bollig A; Sarkar FH; Liao JD
Clin Cancer Res; 2005 Aug; 11(16):6075-86. PubMed ID: 16115953
[TBL] [Abstract][Full Text] [Related]
32. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome.
Bold RJ; Virudachalam S; McConkey DJ
J Surg Res; 2001 Sep; 100(1):11-7. PubMed ID: 11516199
[TBL] [Abstract][Full Text] [Related]
33. Silencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance of pancreatic cancer cells.
Shrikhande SV; Kleeff J; Kayed H; Keleg S; Reiser C; Giese T; Büchler MW; Esposito I; Friess H
Anticancer Res; 2006; 26(5A):3265-73. PubMed ID: 17094439
[TBL] [Abstract][Full Text] [Related]
34. Melatonin is involved in the apoptosis and necrosis of pancreatic cancer cell line SW-1990 via modulating of Bcl-2/Bax balance.
Xu C; Wu A; Zhu H; Fang H; Xu L; Ye J; Shen J
Biomed Pharmacother; 2013 Mar; 67(2):133-9. PubMed ID: 23245210
[TBL] [Abstract][Full Text] [Related]
35. Silencing of IGHG1 reverses the resistance of pancreatic cancer to multidrug chemotherapy by modulating autophagy.
Tian Y; Han W; Fu L; Lv K; Zhou X
Environ Toxicol; 2023 Aug; 38(8):1835-1845. PubMed ID: 37186415
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous knock-down of Bcl-xL and Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells.
Takahashi H; Chen MC; Pham H; Matsuo Y; Ishiguro H; Reber HA; Takeyama H; Hines OJ; Eibl G
Biochim Biophys Acta; 2013 Dec; 1833(12):2980-2987. PubMed ID: 23954445
[TBL] [Abstract][Full Text] [Related]
37. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status.
Violette S; Poulain L; Dussaulx E; Pepin D; Faussat AM; Chambaz J; Lacorte JM; Staedel C; Lesuffleur T
Int J Cancer; 2002 Apr; 98(4):498-504. PubMed ID: 11920608
[TBL] [Abstract][Full Text] [Related]
38. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins.
Nita ME; Nagawa H; Tominaga O; Tsuno N; Fujii S; Sasaki S; Fu CG; Takenoue T; Tsuruo T; Muto T
Br J Cancer; 1998 Oct; 78(8):986-92. PubMed ID: 9792140
[TBL] [Abstract][Full Text] [Related]
39. Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.
Bhutia YD; Hung SW; Krentz M; Patel D; Lovin D; Manoharan R; Thomson JM; Govindarajan R
PLoS One; 2013; 8(1):e53436. PubMed ID: 23335963
[TBL] [Abstract][Full Text] [Related]
40. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ
J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]